Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience-Reference-Cited by-同舟云学术

Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience

Published:2015-08 Issue:8 Volume:110 Page:1186-1196
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Fréling Estelle,Baumann Cédric,Cuny Jean-François,Bigard Marc-André,Schmutz Jean-Luc,Barbaud Annick,Peyrin-Biroulet Laurent

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg2015205.pdf

Reference42 articles.

1. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.;Clark;Gastroenterology,2007

2. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics.;Williet;Inflamm Bowel Dis,2012

3. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohns disease.;Peyrin-Biroulet;Gut,2011

4. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review.;Moustou;J Am Acad Dermatol,2009

5. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.;Moran;Aliment Pharmacol Ther,2013

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor necrosis factor regulates leukocyte recruitment but not bacterial persistence during Staphylococcus aureus craniotomy infection;Journal of Neuroinflammation;2024-07-23

2. Development of a Risk Prediction Model for Adverse Skin Events Associated with TNF-α Inhibitors in Rheumatoid Arthritis Patients;Journal of Clinical Medicine;2024-07-11

3. Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED Trial;Inflammatory Bowel Diseases;2024-03-20

4. Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease;Journal of Pediatric Gastroenterology and Nutrition;2023-12-10

5. Cutaneous immune-related phenomena in patients with inflammatory arthritides treated with biological therapies: Clinical and pathophysiological considerations;Seminars in Arthritis and Rheumatism;2023-12